Cambium Bio (ASX:CMB) EBITDA Margin %: 0.00% (As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
34 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio EBITDA Margin %?

Cambium Bio ASX:CMB -6.74% 34 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Cambium Bio ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cambium Bio's EBITDA for the six months ended in Dec. 2025 was A$-1.44 Mil. Cambium Bio's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Cambium Bio's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Cambium Bio  (ASX:CMB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Cambium Bio EBITDA Margin % Related Terms

Cambium Bio EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Cambium Bio's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio EBITDA Margin % Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -198,400.00 0.00

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:CMB vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Cambium Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cambium Bio's EBITDA Margin % falls into.


ASX:CMB
34GF Score
Cambium Bio Ltd ASX:CMB
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cambium Bio's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.804/0
= %

Cambium Bio's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.439/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Cambium Bio (ASX:CMB) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #999999 out of 944 companies in the Biotechnology industry.
Is Cambium Bio's EBITDA Margin % too high?
Cambium Bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, Cambium Bio ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #999999 out of 944 companies for EBITDA Margin %. This places Cambium Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cambium Bio and its competitors. Cambium Bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Cambium Bio's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
34GF Score

Get the complete analysis for ASX:CMB

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price